Dr. Ferris on the Safety Profile for RTOG 3504 for Head and Neck Cancer
Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the safety profile of the RTOG 3504 trial for patients with head and neck cancer.
Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the safety profile of the RTOG 3504 trial for patients with head and neck cancer
For the RTOG 3504 trial, the phase I component is still ongoing. According to Ferris, it would be a surprise if there was a dose-limiting toxicity, partly because there are some investigator sponsored trials with both nivolumab (Opdivo) and pembrolizumab (Keytruda), which released safety data.
